Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Acute ischemic stroke (AIS) is a life-threatening thrombotic disorder, with intravenous thrombolysis (IVT) serving as the first-line treatment during its acute phase. However, thrombolysis resistance diminishes the success rate of early reperfusion. Recent studies have highlighted neutrophil extracellular traps (NETs) as a critical factor contributing to thrombolysis resistance. Targeting NETs with deoxyribonuclease I (DNase I) has been shown to significantly improve the thrombolytic efficacy of recombinant tissue plasminogen activator (rt-PA) and reduce the risk of hemorrhagic transformation. In this review, we summarize current knowledge on the mechanisms by which NETs contribute to thrombosis and thrombolysis resistance, explore the prospective and feasibility of targeting NETs to improve thrombolysis, providing information about the creation of innovative thrombolytic treatment approaches for AIS.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-2609-3457DOI Listing

Publication Analysis

Top Keywords

thrombolysis resistance
16
neutrophil extracellular
8
extracellular traps
8
treatment acute
8
acute ischemic
8
ischemic stroke
8
targeting nets
8
thrombolysis
6
targeting neutrophil
4
traps strategy
4

Similar Publications

Remote ischemic conditioning (RIC) is a simple, non-invasive procedure that has been shown to be safe and feasible in multiple smaller clinical trials. Recent large randomized controlled trials have yielded mixed results regarding clinical effect. Patients with severe stroke may experience greater benefit from cerebroprotective interventions, highlighting the need for adjunctive therapies to enhance endovascular therapy (EVT) outcomes.

View Article and Find Full Text PDF

Predictors of early resistance to catheter-directed thrombolysis in patients with proximal deep vein thrombosis.

Eur J Radiol

August 2025

Department of Interventional and Vascular Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, PR China. Electronic address:

Purpose: To determine predictors of immediate thrombolysis resistance (iTR) in patients with proximal deep vein thrombosis (DVT), defined as thrombosis involving the femoral or more proximal veins, with or without concomitant popliteal vein involvement, and to investigate its impact on long-term post-thrombotic syndrome (PTS) outcomes.

Methods: This single-center retrospective study reviewed consecutive patients who underwent catheter-directed thrombolysis (CDT) as first-line therapy. Baseline demographics, clinical history, comorbidities and provoking risk factors for DVT, intraprocedural findings, periprocedural complications, and follow-up outcomes were compared between the iTR and immediate thrombolysis success (iTS) groups.

View Article and Find Full Text PDF

N-acetylcysteine (NAC) as an adjunct to intravenous fibrinolysis in patients with acute ischemic stroke: a single group study (NAC-Safety).

Neuroscience

August 2025

Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institut Blood and Brain @ Caen-Normandie (BB@C), 14000 Caen, France; Department of Neurology, Caen-Normandie University Hospital, CHU, Caen, France.

Recombinant tissue plasminogen activator (alteplase) and its derivative tenecteplase are approved for acute ischemic stroke (AIS), but their low recanalization rates remain a limitation. Resistance to intravenous (IV) fibrinolysis may arise from platelet cross-linking during arterial thrombosis, mediated by von Willebrand factor (VWF) multimers. N-Acetylcysteine (NAC) has demonstrated potential to cleave large VWF multimers in preclinical studies, suggesting its potential as an adjunct therapy.

View Article and Find Full Text PDF

Acute pulmonary thromboembolism represents a critical, life-threatening condition that necessitates immediate and effective management to minimize associated mortality. Although the current recommendation for managing hemodynamically unstable pulmonary embolism (PE) is the regimen of 100 mg recombinant tissue plasminogen activator (rtPA) administered over two hours, an accelerated regimen of rtPA (0.6 mg/kg over 15 minutes, maximum 50 mg) has also been described for the management of PE and circulatory arrest.

View Article and Find Full Text PDF

Cardiovascular diseases and stroke together account for the largest causes of death in Western countries. These pathologies are directly linked to the formation of blood clots that block blood flow to vital organs. Common risk factors for such clots are obesity, high blood pressure, diabetes, and high LDL cholesterol.

View Article and Find Full Text PDF